TRIBOO SPA (TB.MI) Fundamental Analysis & Valuation

BIT:TB • IT0005001554

Current stock price

0.355 EUR
+0.01 (+2.31%)
Last:

This TB.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. TB.MI Profitability Analysis

1.1 Basic Checks

  • In the past year TB has reported negative net income.
  • TB had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: TB reported negative net income in multiple years.
  • TB had a positive operating cash flow in 4 of the past 5 years.
TB.MI Yearly Net Income VS EBIT VS OCF VS FCFTB.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M 15M

1.2 Ratios

  • The Return On Assets of TB (-10.01%) is worse than 77.27% of its industry peers.
  • TB has a worse Return On Equity (-46.00%) than 74.24% of its industry peers.
Industry RankSector Rank
ROA -10.01%
ROE -46%
ROIC N/A
ROA(3y)-5.16%
ROA(5y)-2.73%
ROE(3y)-24.65%
ROE(5y)-13.41%
ROIC(3y)N/A
ROIC(5y)N/A
TB.MI Yearly ROA, ROE, ROICTB.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

  • TB's Gross Margin of 96.72% is amongst the best of the industry. TB outperforms 93.94% of its industry peers.
  • TB's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for TB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.87%
GM growth 5YN/A
TB.MI Yearly Profit, Operating, Gross MarginsTB.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. TB.MI Health Analysis

2.1 Basic Checks

  • TB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TB has about the same amout of shares outstanding than it did 1 year ago.
  • TB has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for TB is higher compared to a year ago.
TB.MI Yearly Shares OutstandingTB.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
TB.MI Yearly Total Debt VS Total AssetsTB.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of 0.25, we must say that TB is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.25, TB is doing worse than 78.79% of the companies in the same industry.
  • A Debt/Equity ratio of 0.94 indicates that TB is somewhat dependend on debt financing.
  • TB has a Debt to Equity ratio of 0.94. This is comparable to the rest of the industry: TB outperforms 43.94% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF N/A
Altman-Z 0.25
ROIC/WACCN/A
WACC5.21%
TB.MI Yearly LT Debt VS Equity VS FCFTB.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 0.80 indicates that TB may have some problems paying its short term obligations.
  • TB has a worse Current ratio (0.80) than 63.64% of its industry peers.
  • A Quick Ratio of 0.77 indicates that TB may have some problems paying its short term obligations.
  • The Quick ratio of TB (0.77) is worse than 62.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.8
Quick Ratio 0.77
TB.MI Yearly Current Assets VS Current LiabilitesTB.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. TB.MI Growth Analysis

3.1 Past

  • TB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -60.50%.
  • Looking at the last year, TB shows a very negative growth in Revenue. The Revenue has decreased by -17.66% in the last year.
  • The Revenue has been decreasing by -3.87% on average over the past years.
EPS 1Y (TTM)-60.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%138.05%
Revenue 1Y (TTM)-17.66%
Revenue growth 3Y-13.12%
Revenue growth 5Y-3.87%
Sales Q2Q%-18.03%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • TB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -3.30% yearly.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-11.59%
Revenue Next 2Y-3.3%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
TB.MI Yearly Revenue VS EstimatesTB.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
TB.MI Yearly EPS VS EstimatesTB.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2025 2026 0 0.05 -0.05 0.1 0.15 0.2

More info and screens

Find the best growth stocksShow best growing peers

3

4. TB.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • TB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 5.74, which indicates a rather cheap valuation of TB.
  • Based on the Price/Forward Earnings ratio, TB is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of TB to the average of the S&P500 Index (22.10), we can say TB is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 5.74
TB.MI Price Earnings VS Forward Price EarningsTB.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

  • TB's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.47
TB.MI Per share dataTB.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TB.MI Dividend Analysis

5.1 Amount

  • TB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TB.MI Fundamentals: All Metrics, Ratios and Statistics

TRIBOO SPA

BIT:TB (3/19/2026, 7:00:00 PM)

0.355

+0.01 (+2.31%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)03-12
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners58.57%
Ins Owner ChangeN/A
Market Cap9.88M
Revenue(TTM)56.29M
Net Income(TTM)-8.74M
Analysts40
Price Target0.49 (38.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.01
Dividend Growth(5Y)-27.05%
DP-4.59%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)150%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-17.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.74
P/S 0.18
P/FCF N/A
P/OCF 5.26
P/B 0.52
P/tB N/A
EV/EBITDA 8.47
EPS(TTM)-0.31
EYN/A
EPS(NY)0.06
Fwd EY17.41%
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)0.07
OCFY19%
SpS2.02
BVpS0.68
TBVpS-0.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.01%
ROE -46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.72%
FCFM N/A
ROA(3y)-5.16%
ROA(5y)-2.73%
ROE(3y)-24.65%
ROE(5y)-13.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.87%
GM growth 5YN/A
F-Score3
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF N/A
Debt/EBITDA 5.69
Cap/Depr 55.78%
Cap/Sales 6.26%
Interest Coverage N/A
Cash Conversion 59.5%
Profit Quality N/A
Current Ratio 0.8
Quick Ratio 0.77
Altman-Z 0.25
F-Score3
WACC5.21%
ROIC/WACCN/A
Cap/Depr(3y)76.16%
Cap/Depr(5y)73.16%
Cap/Sales(3y)7.86%
Cap/Sales(5y)7.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%138.05%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-17.66%
Revenue growth 3Y-13.12%
Revenue growth 5Y-3.87%
Sales Q2Q%-18.03%
Revenue Next Year-11.59%
Revenue Next 2Y-3.3%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-152.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y80.27%
FCF growth 3Y-73.74%
FCF growth 5YN/A
OCF growth 1Y213.29%
OCF growth 3Y-30.09%
OCF growth 5Y-11%

TRIBOO SPA / TB.MI Fundamental Analysis FAQ

What is the fundamental rating for TB stock?

ChartMill assigns a fundamental rating of 1 / 10 to TB.MI.


What is the valuation status for TB stock?

ChartMill assigns a valuation rating of 3 / 10 to TRIBOO SPA (TB.MI). This can be considered as Overvalued.


What is the profitability of TB stock?

TRIBOO SPA (TB.MI) has a profitability rating of 2 / 10.


Is the dividend of TRIBOO SPA sustainable?

The dividend rating of TRIBOO SPA (TB.MI) is 0 / 10 and the dividend payout ratio is -4.59%.